Objective
to present the five-year clinical outcomes of percutaneous treatment with biodegradable polymer-coated sirolimus stent (BP-SES) compared to durable polymer-coated sirolimus stent (DP-SES)
Study
single blind, multicentre non-inferior randomised trial (2:1)
Population
patients with stable CAD or ACS
Endpoints
target lesion failure as cardiac death, target vessel MI or clinically indicated target lesion revascularisation at 5 years
Conclusion
the 5-year adverse clinical outcomes were similar between treatment with BP-SES and DP-SES stents
Xu et al. EuroIntervention. 2021;16:e1518-26
